ENYO Pharma in the Top 50 of the EIC ScalingUp List

Published on 10/12/2021

ENYO Pharma is in the Top 50 of the EIC ScalingUp List, in the Health Track. We were selected out of a universe of 3,000+ deeptech startups, as funded so far by the European Innovation Council (EIC) or SME Instrument. This is a fantastic business support for the growth of the company during this pivotal year.

https://www.eicscalingup.eu/top50

Read next in 'Latest news'

• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters